Monday, 5 October 2009
Ballroom East (CTICC)
Contraception and Beyond: Evidence-based Indications for LNG-IUS
1. Wider Use of Intrauterine Contraception - David Grimes
2. The LNG-IUS in Heavy Menstrual Bleeding: First-line Treatment Based on Comprehensive Clinical Data - Anita Nelson 3. Safety and Efficacy of Consecutive Use of the LNG-IUS - Confirmed by a New Study -Kristina Gemzell-Danielsson Symposium sponsored by Bayer Schering Pharma
Ballroom West (CTICC)
The Role of GARDASIL™ in Reducing the Global Burden of Cervical Cancer and

Other HPV-Related Diseases
1. Opening Remarks – Lynette Denny, South Africa
2. Global HPV Epidemiology and Burden of Disease - Lynette Denny, South Africa3. Gardasil Efficacy and Recent Clinical Data - Suzanne M. Garland, Australia 4. MSD’s Commitment: Access to Gardasil in the Developing World - Carlos Sattler, USA Symposium sponsored by MSD
Tuesday, 6 October 2009
Ballroom East (CTICC)
Innovation in Contraception
1. Ethinylestradiol 20mcg/Drospirenone 3mg Administered in a 24/4 Regimen: A New OC
Goes Beyond Contraception - Joachim Marr and Lorraine Dennerstein
2. A New OC Concept with Additional Benefit - Wolfgang Holzgreve and Klaus Pietrzik Symposium sponsored by Bayer Schering Pharma
Ballroom West (CTICC)
Overactive Bladder: TIME to take notice
Chairman’s Introduction
1. The Burden and Implications of OAB – Linda Cardozo, UK2. Initial Diagnosis and Assessment of Women with LUTS - Mickey Karram, USA3. Making Sure We Understand Our Patient’s Needs – Peter de Jong, South Africa 4. Ensuring Successful Management with Pharmacotherapy - Willy Davilla, USA Symposium sponsored by Astellas Pharma
Wednesday, 7 October 2009
Ballroom East (CTICC)
Evolution of a Revolution: Introducing a New Class of Oral Contraceptive
1. Introducing E2V/DNG - Ian Fraser2. E2V/DNG: Contraceptive Efficacy and Safety Data - Jeffrey T. Jensen 3. First Experience with the Estradiol Based Combined Oral Contraceptive E2V/DNG - Diana Mansour Symposium sponsored by Bayer Schering Pharma
Ballroom West (CTICC)
Effective Solutions for Enhanced Obstetric Management
1. New Ultrasound Technologies in Assisted Reproductive Medicine SonoAVC - Nick Raine
Fenning, Nottingham, UK
2. Enhancing the Monitoring Experience from Antepartum through to Postpartum - Philippe Barjot, Caen, France 3. Improving Obstetric Workflow, Archiving and Reporting - Philippe Barjot, Caen, France Symposium sponsored by GE Healthcare
Thursday, 8 October 2009
Ballroom East (CTICC)
Improving Women's Healthcare - a Contemporary View
Chair: Jennifer Blake
1. Progestins - An Important Versatile Class – Peter Rogers
2. Specialised Progestins I - Dienogest in Endometriosis - Alfred Mueck3. Specialised Progestins II – Drospirenone in Menopause - Tommaso Simoncini Symposium sponsored by Bayer Schering Pharma
Ballroom West (CTICC)
Cervarix®: Focusing on the Global Needs of Cervical Cancer Vaccination
1. Welcome and Introduction – Anne Szarewski, UK and Hugues Bogaerts, Belgium
2. The Relevance of the HPV Type Distribution in Cervical Cancer – F. Xavier Bosch, Spain3. Understanding the Immunological Potential of HPV Vaccines – Peter L. Stern, UK4. Cervarix®: The Benefits to Girls and Women: From Clinical Trials to Clinical Practice – Anne Symposium sponsored by GlaxoSmithKline


Sca protocol for the prevention of tick-borne illness

SCA Protocol for the Prevention of Tick-Borne Illness Because SCA has experienced increased incidence of embedded ticks and Lyme disease, when working in areas with known high populations of ticks and based on a job hazard assessment, the following protocol for the prevention of tick borne illnesses has been developed. 1. Cease or do not engage in service in areas with an unmanageabl

Tamiflu users often experience side effects, according to consumer ratings database

Tamiflu users say side effects are common One-third of patients report nausea; some children experience mental conditions Nausea, headaches and vomiting are the most common side effects of the popular flu drug Tamiflu—and they occur more severely in young children than adults, consumers tell Tamiflu ( oseltamivir phosphate) is approved for children over 1, but Askapat

Copyright ©2010-2018 Medical Science